Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial
- Registration Number
- TCTR20210708001
- Lead Sponsor
- Thai Traditional Medicine Knowlegde funding
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 63
1) age 18 to 60 years
2) diagnosis of SARS-CoV-2 infection by positive rRT-PCR test
3) being admitted to hospital within 72 hours of illness
4) presence of any signs and symptoms of mild COVID-19 (e.g., fever, cough, sore throat, malaise, headache, and diarrhea)
5) not having signs and symptoms of pneumonia or abnormal chest imaging
1)Patient who be treated with any antiviral drugs i.e. favipiravir, remdesivir, Lopinavir, ritonavir, interferon (b1a), chloroquine or hydroxychloroquine
2) History of allergy to A. paniculata
3) Pregnancy or during lactation
4) Patient who has underlying medical conditions that increase risk of severe COVID-19
5) Patient with history of rheumatic heart disease and/or renal dysfunction due to Streptococcus group A
6) Patient who be treated with anticoagulants i.e., clopidogrel, warfarin, and aspirin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method symptom severity 5 days visual anolog scale
- Secondary Outcome Measures
Name Time Method duration of illness symptoms 5 days visaul anolog scale score and prescibing of symptomatic drugs,Events of pneumonia 14 days number of events,Inflamatory cytokines 5 days C-reactive proteins